- Arrowhead Pharmaceuticals Presents New Phase 2 Data of Plozasiran in Patients with Mixed Hyperlipidemia
- Arrowhead Pharmaceuticals Presents New Clinical Data Showing ARO-RAGE Achieves High Level of Gene Knockdown in Patients with Asthma
- Arrowhead Pharmaceuticals Reports Fiscal 2024 Second Quarter Results
- Arrowhead Pharmaceuticals Earns $50 Million Milestone from Royalty Pharma
- Arrowhead Pharmaceuticals to Participate in Upcoming May 2024 Conferences
- Arrowhead Pharmaceuticals to Host 2024 Summer Series of R&D Webinars
- Arrowhead Pharmaceuticals to Webcast Fiscal 2024 Second Quarter Results
- Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-CFB for Treatment of Complement Mediated Kidney Disease
- Arrowhead Pharmaceuticals Announces New Phase 2 Data of Plozasiran Published in JAMA Cardiology and Presented at American College of Cardiology 73rd Annual Scientific Session & Expo
- Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
More ▼
Key statistics
On Tuesday, Arrowhead Pharmaceuticals Inc (ARWR:NSQ) closed at 23.92, 15.72% above the 52 week low of 20.67 set on Dec 01, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 24.76 |
---|---|
High | 25.30 |
Low | 23.41 |
Bid | 22.50 |
Offer | 31.80 |
Previous close | 23.92 |
Average volume | 912.88k |
---|---|
Shares outstanding | 124.20m |
Free float | 118.64m |
P/E (TTM) | -- |
Market cap | 2.97bn USD |
EPS (TTM) | -4.24 USD |
Data delayed at least 15 minutes, as of May 28 2024 21:00 BST.
More ▼